HHLR Advisors, LTD. holds a concentrated book of 38 stocks worth $1.7B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Marvell Technology Inc and trimmed PDD Holdings Inc. Their largest long position is PDD Holdings Inc at 25% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1762304/holdings"
Use Arkolith to show HHLR ADVISORS, LTD.'s latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | PDD Holdings Inc SPONSORED ADS | $425.6M | 4.17M | 25.4% | ▼−61% Reduced · −6.6M sh | |
| 2 | Alibaba Group Hldg Ltd SPONSORED ADS | $307.8M | 2.45M | 18.4% | ▼−55% Reduced · −3.0M sh | |
| 3 | Beone Medicines Ltd SPONSORED ADS | $307.2M | 1.03M | 18.4% | —Held | |
| 4 | Futu Hldgs Ltd SPON ADS CL A | $194.1M | 1.42M | 11.6% | ▼−13% Reduced · −211K sh | |
| 5 | Legend Biotech Corp SPONSORED ADS | $108.3M | 5.98M | 6.5% | —Held | |
| 6 | Arrivent Biopharma Inc COM | $90.6M | 3.93M | 5.4% | —Held | |
| 7 | Ke Hldgs Inc SPONSORED ADS | $63.4M | 4.24M | 3.8% | —Held | |
| 8 | Clearwater Analytics Hldgs I CL A | $32.3M | 1.37M | 1.9% | —Held | |
| 9 | Cytek Biosciences Inc COM | $29.1M | 6.66M | 1.7% | —Held | |
| 10 | Marvell Technology Inc COM | $16.9M | 171.0K | 1.0% | ▲New New position | |
| 11 | Yatsen Hldg Ltd SPONSORED ADS | $15.0M | 4.89M | 0.9% | —Held | |
| 12 | Novabridge Biosciences SPONSORED ADS | $14.7M | 5.98M | 0.9% | —Held | |
| 13 | Maze Therapeutics Inc COM | $10.9M | 366.0K | 0.7% | ▼−20% Reduced · −92K sh | |
| 14 | Contineum Therapeutics Inc CL A | $8.7M | 669.3K | 0.5% | —Held | |
| 15 | Agora Inc ADS | $7.4M | 2.10M | 0.4% | —Held | |
| 16 | Webull Corp ORD SHS | $7.2M | 1.50M | 0.4% | ▼−75% Reduced · −4.5M sh | |
| 17 | Taiwan Semiconductor Manufac SPONSORED ADS | $5.2M | 15.5K | 0.3% | ▲+37% Added · +4K sh | |
| 18 | Sagimet Biosciences Inc COM SER A | $3.8M | 724.8K | 0.2% | —Held | |
| 19 | Tuya Inc SPONSERED ADS | $3.6M | 1.56M | 0.2% | —Held | |
| 20 | Ge Aerospace COM NEW | $2.8M | 10.0K | 0.2% | —Held | |
| 21 | Vipshop Hldgs Ltd SPONSORED ADS A | $2.0M | 124.7K | 0.1% | ▲New New position | |
| 22 | Mogu Inc SPON ADS | $1.9M | 847.5K | 0.1% | —Held | |
| 23 | Gossamer Bio Inc COM | $1.6M | 4.97M | 0.1% | —Held | |
| 24 | Intel Corp COM | $1.3M | 29.0K | 0.1% | ▲New New position | |
| 25 | Pacific Biosciences Calif In COM | $1.2M | 918.9K | 0.1% | —Held | |
| 26 | Equinox Gold Corp COM | $1.2M | 80.5K | 0.1% | —Held | |
| 27 | Nvidia Corporation COM | $1.2M | 6.6K | 0.1% | ▲New New position | |
| 28 | Lumentum Hldgs Inc COM | $1.1M | 1.5K | 0.1% | ▲New New position | |
| 29 | Corning Inc COM | $1.0M | 7.7K | 0.1% | ▲New New position | |
| 30 | Barrick MNG Corp COM SHS | $1.0M | 25.4K | 0.1% | —Held | |
| 31 | Coherent Corp COM | $1.0M | 4.3K | 0.1% | ▲New New position | |
| 32 | Dingdong Cayman Ltd ADS | $911K | 354.5K | 0.1% | ▲New New position | |
| 33 | Centrais Elet Bras Sa SPONSORED ADR | $712K | 63.1K | 0.0% | ▼−35% Reduced · −34K sh | |
| 34 | Ishares Inc MSCI MEXICO ETF | $662K | 8.8K | 0.0% | ▲New New position | |
| 35 | Aligos Therapeutics Inc COM NEW | $567K | 76.2K | 0.0% | —Held | |
| 36 | Vnet Group Inc SPONSORED ADS A | $546K | 65.1K | 0.0% | ▲+23% Added · +12K sh | |
| 37 | Uxin Ltd SPONSORED ADS | $59K | 19.2K | 0.0% | —Held | |
| 38 | Ridgetech Inc SHS NEW | $657 | 20.2K | 0.0% | —Held |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 38 | $1.7B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 33 | $3.1B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 33 | $4.1B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 36 | $3.1B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 49 | $3.5B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 45 | $2.9B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 48 | $4.6B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 78 | $4.1B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 14, 2024 | 63 | $4.6B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 49 | $5.0B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 60 | $4.5B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 60 | $4.7B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 70 | $5.6B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 67 | $4.7B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 61 | $3.8B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 64 | $4.7B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 64 | $4.8B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 76 | $6.5B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 | 85 | $7.6B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 89 | $9.7B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 91 | $10.1B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 12, 2021 | 95 | $12.6B | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 16, 2020 | 89 | $13.2B | 13F-HR |
| Q2 2020 | Jun 30, 2020 | Aug 14, 2020 | 74 | $10.9B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.